

CPD questionnaires must be completed online at <https://members.samedical.org/>

**Please note: The change in CPD question format comes from the accreditation bodies, who have informed us that CPD questionnaires must consist of a minimum of 5 questions, 80% of which should be MCQs with a minimum of 4 options and only 20% of which may now be in the form of 'True or false' answers.**

**MCQs may be of 'single correct answer' or 'multiple correct answer' format. Where the question states that more than one answer is correct, choose more than one of *i, ii, iii* or *iv* (anything from two to all answers may be correct), and then select the correct combination from answers a, b, c or d. Where the question states that only one answer is correct, mark the single answer that you think is correct.**

#### Regarding possible private health funding reform scenarios for the National Health Insurance Act

- When was the National Health Insurance Act No. 20 of 2023 signed into law? (one answer is correct)
  - February 2024
  - March 2024
  - April 2024
  - May 2024.
- Which of the following statements is correct regarding medical schemes in terms of the National Health Insurance Act? (one answer is correct)
  - Once National Health Insurance (NHI) has been fully implemented as determined by the health minister through regulations in the Government Gazette, medical schemes may only offer complementary cover to services not reimbursable by the NHI Fund.
  - Once NHI has been fully implemented as determined by the health minister through regulations in the Government Gazette, medical schemes may offer complementary cover to services even if reimbursable by the NHI Fund.
  - Once NHI has been fully implemented as determined by the health minister through regulations in the Government Gazette, medical schemes may offer complementary and other cover to services reimbursable by the NHI Fund.
  - Once NHI has been fully implemented as determined by the health minister through regulations in the Government Gazette, medical schemes may not offer complementary cover to services not reimbursable by the NHI Fund.
- According to the National Department of Health, in how many phases will the NHI Act be implemented? (one answer is correct)
  - one
  - two
  - three
  - four.

#### Regarding orthopaedic-related pathological conditions in the paediatric population presenting at outreach clinics

- Which of the following statements is correct? (one answer is correct)
  - Orthopaedic disease refers to abnormalities and symptomatology of the musculoskeletal and endocrine systems.
  - Orthopaedic disease refers to abnormalities and symptomatology of the musculoskeletal and cardiovascular systems.
  - Orthopaedic disease refers to abnormalities and symptomatology of the musculoskeletal and neurological systems.

d. Orthopaedic disease refers to abnormalities and symptomatology of the musculoskeletal and urological systems.

5. Which of the following are underlying causes of orthopaedic disease in the paediatric population? (more than one answer is correct)

- congenital
- developmental
- acquired
- drug induced.

- i, ii*
- i, ii, iii*
- i, iii, iv*
- i, iii.*

6. On what is the South African (SA) birth defect surveillance system modelled? (one answer is correct)

- the International Clearinghouse for congenital disorders monitoring systems
- the National Clearinghouse for congenital disorders monitoring systems
- the International Disorders house for congenital disorders monitoring systems
- the National Disorders house for congenital disorders monitoring systems.

#### Regarding a proposed dashboard for monitoring District Health System performance in South Africa

- What is a health dashboard? (one answer is correct)
  - A health dashboard is an as-close-to-real-time-as-possible clinical tool designed to provide an accessible overview of key health indicators, enabling health managers at all levels to respond quickly to emerging trends, and make informed decisions.
  - A health dashboard is an as-close-to-real-time-as-possible data-driven tool designed to provide an accessible overview of key health indicators, enabling health managers at all levels to respond quickly to emerging trends, and make informed decisions.
  - A health dashboard is an as-close-to-real-time-as-possible surgical tool designed to provide an accessible overview of key health indicators, enabling health managers at all levels to respond quickly to emerging trends, and make informed decisions.
  - A health dashboard is an as-close-to-real-time-as-possible paediatric-based tool designed to provide an accessible overview of key health indicators, enabling health managers at all levels to respond quickly to emerging trends, and make informed decisions.

**A maximum of 3 CEUs will be awarded per correctly completed test.**

#### INSTRUCTIONS

- Read the journal. All the answers will be found there.
- Go to <https://members.samedical.org/> to answer the questions.

Accreditation number: MDB015/MPDP/038/400



CPD questionnaires must be completed online at <https://members.samedical.org/>

**Please note: The change in CPD question format comes from the accreditation bodies, who have informed us that CPD questionnaires must consist of a minimum of 5 questions, 80% of which should be MCQs with a minimum of 4 options and only 20% of which may now be in the form of 'True or false' answers.**

MCQs may be of 'single correct answer' or 'multiple correct answer' format. Where the question states that more than one answer is correct, choose more than one of *i, ii, iii* or *iv* (anything from two to all answers may be correct), and then select the correct combination from answers a, b, c or d. Where the question states that only one answer is correct, mark the single answer that you think is correct.

8. Why should there be regular assessments of health systems performance? (more than one answer is correct)
- to help to identify priorities
  - to help to inform decisions
  - to help to ensure the most appropriate responses to the priorities
  - to help to deliver interventions where required.
- ii, iii*
  - ii, iii, iv*
  - i, ii, iii*
  - i, iii.*

**Regarding the prevalence, risk factors and outcomes of retinopathy of prematurity at a tertiary care centre in South Africa**

9. What is the global estimate of the number of infants diagnosed with retinopathy of prematurity annually? (one answer is correct)
- 20 000
  - 30 000
  - 40 000
  - 50 000.
10. How many infants are at risk of developing retinopathy of prematurity annually in SA? (one answer is correct)
- 14 000
  - 15 000
  - 16 000
  - 17 000.
11. What is bevacizumab? (one answer is correct)
- a growth hormone
  - a monoclonal vascular endothelial growth factor
  - a type of endocrine replacement therapy
  - a monoclonal anti-vascular endothelial growth factor.

**Regarding tracking of poison ingestion deaths for South Africa**

12. What is terbufos? (more than one answer is correct)
- a treatment for organophosphate poisoning
  - a pesticide registered in SA for agricultural use
  - an organophosphate registered in SA for agricultural use
  - a treatment for severe burns.
- i, ii, iv*
  - ii, iii*
  - ii, iii, iv*
  - i, iv.*

**Regarding progress in advanced cellular and gene therapies in South Africa and barriers to patient access**

13. What do cellular therapy products encompass? (more than one answer is correct)
- regenerative medicine
  - biomedical research interventions
  - adoptive cell therapies
  - hormone replacement therapy.
- i, ii, iv*
  - ii, iii*
  - i, ii, iii*
  - i, iii.*
14. Which of the following statements is true regarding advanced cell and gene therapy? (one answer is correct)
- SA lacks a regulatory framework for advanced cell and gene therapies.
  - Advanced cell and gene therapies are well covered by the Medicines and Related Substances Act No. 101 of 1965.
  - Advanced cell and gene therapies are well covered by the National Health Act No. 61 of 2003.
  - Advanced cell and gene therapies are well covered by the Genetically Modified Organisms Act No. 15 of 1997.
15. What are the major drivers of costs as a main barrier to implementing robust local manufacturing capacity for advanced cell and gene therapies? (more than one answer is correct)
- vector costs
  - the expense of shipping good manufacturing practice-grade products from centralised manufacturing
  - pharmaceutical manufacturing costs
  - infrastructure costs.
- i, ii, iii*
  - i, ii*
  - ii, iii, iv*
  - i, iii, iv.*

**A maximum of 3 CEUs will be awarded per correctly completed test.**

**INSTRUCTIONS**

- Read the journal. All the answers will be found there.
- Go to <https://members.samedical.org/> to answer the questions.

Accreditation number: MDB015/MPDP/038/400

